three MS treatments
03 February, 2020

Three MS treatments will be considered for inclusion on the PBS at a PBAC meeting in March – nabiximols (Sativex), siponimod (Mayzent), ozanimod (Zeposia).

13 December, 2019

MS Research Australia has funded six new MS studies totalling almost $150,000 in the first round of incubator […]

13 December, 2019

Associate Professor Kaylene Young and Professor Bruce Taylor are working towards new discoveries that may provide treatments to […]

13 December, 2019

The MS Research Australia biennial Progress in MS Research Conference was recently held in Melbourne. Over 150 MS […]

12 December, 2019

A great way to stay up-to-date on the latest progress in MS research is by joining us in cyber-space […]

13 November, 2019

The first ever treatment for secondary progressive MS, a form of MS that can follow on from relapsing remitting MS, has been approved in Australia.

15 October, 2019

Although there has been quite a bit of research into the contribution of genes to the risk of […]

14 October, 2019

Myelin oligodendrocyte glycoprotein (MOG) antibody is associated with many demyelinating conditions, but it has not be characterised in-depth. […]

21 September, 2019

Australian researchers funded by MS Research Australia have potentially found new neurodegenerative biomarkers for MS progression.

21 September, 2019

A large international study led by an Australian researcher has identified risk factors that may contribute to conversion to secondary progressive MS.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search